Patents by Inventor Fabrizio De Benedetti

Fabrizio De Benedetti has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS, COMPOSITIONS AND DOSING REGIMENS FOR TREATING OR PREVENTING INTERFERON-GAMMA RELATED INDICATIONS
    Publication number: 20240010719
    Abstract: The disclosure relates generally to methods compositions and dosing regimens for treating, preventing and/or delaying the onset or progression of, or alleviating a symptom associated with elevated IFN-? levels.
    Type: Application
    Filed: July 25, 2023
    Publication date: January 11, 2024
    Inventors: Cristina DE MIN, Walter FERLIN, Fabrizio DE BENEDETTI
  • METHODS, COMPOSITIONS AND DOSING REGIMENS FOR TREATING OR PREVENTING INTERFERON-GAMMA RELATED INDICATIONS
    Publication number: 20220389091
    Abstract: The disclosure relates generally to methods compositions and dosing regimens for treating, preventing and/or delaying the onset or progression of, or alleviating a symptom associated with elevated IFN-? levels.
    Type: Application
    Filed: December 23, 2021
    Publication date: December 8, 2022
    Inventors: Cristina DE MIN, Walter FERLIN, Fabrizio DE BENEDETTI
  • Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications
    Patent number: 11236158
    Abstract: The disclosure relates generally to methods compositions and dosing regimens for treating, preventing and/or delaying the onset or progression of, or alleviating a symptom associated with elevated IFN-? levels.
    Type: Grant
    Filed: March 26, 2020
    Date of Patent: February 1, 2022
    Assignee: Swedish Orphan Biovitrum AG
    Inventors: Cristina De Min, Walter Ferlin, Fabrizio De Benedetti
  • Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications
    Patent number: 11091543
    Abstract: The disclosure relates generally to methods compositions and dosing regimens for treating, preventing and/or delaying the onset or progression of, or alleviating a symptom associated with elevated IFN-? levels.
    Type: Grant
    Filed: October 24, 2017
    Date of Patent: August 17, 2021
    Assignee: Swedish Orphan Biovitrum AG
    Inventors: Cristina de Min, Walter Ferlin, Fabrizio De Benedetti
  • Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of CXCL9 and other biomarkers
    Patent number: 11034760
    Abstract: Methods and compositions for treating hemophagocytic lymphohistiocytosis (HLH) are provided. The disclosure also relates generally to methods and compositions for diagnosing and treating disorders associated with elevated levels of CXCL9, elevated levels of total IFN?, and other biomarkers. The disclosure also relates to methods of treating, delaying the progression of, or otherwise ameliorating a symptom of a disorder in patients with elevated levels of CXCL9 elevated levels of total IFN?, and other biomarkers using agents that interfere with or otherwise antagonize interferon gamma (IFN?) signaling, including neutralizing anti-IFN? antibodies.
    Type: Grant
    Filed: May 9, 2016
    Date of Patent: June 15, 2021
    Assignee: Swedish Orphen Biovitrum AG
    Inventors: Cristina de Min, Walter Ferlin, Fabrizio De Benedetti
  • METHODS AND COMPOSITIONS FOR DIAGNOSIS AND TREATMENT OF DISORDERS IN PATIENTS WITH ELEVATED LEVELS OF CXCL9 AND OTHER BIOMARKERS
    Publication number: 20210101972
    Abstract: Methods and compositions for treating hemophagocytic lymphohistiocytosis (HLH) are provided. The disclosure also relates generally to methods and compositions for diagnosing and treating disorders associated with elevated levels of CXCL9, elevated levels of total IFN?, and other biomarkers. The disclosure also relates to methods of treating, delaying the progression of, or otherwise ameliorating a symptom of a disorder in patients with elevated levels of CXCL9 elevated levels of total IFN?, and other biomarkers using agents that interfere with or otherwise antagonize interferon gamma (IFN?) signaling, including neutralizing anti-IFN? antibodies.
    Type: Application
    Filed: December 14, 2020
    Publication date: April 8, 2021
    Inventors: Cristina DE MIN, Walter FERLIN, Fabrizio DE BENEDETTI
  • METHODS, COMPOSITIONS AND DOSING REGIMENS FOR TREATING OR PREVENTING INTERFERON-GAMMA RELATED INDICATIONS
    Publication number: 20200291110
    Abstract: The disclosure relates generally to methods compositions and dosing regimens for treating, preventing and/or delaying the onset or progression of, or alleviating a symptom associated with elevated IFN-? levels.
    Type: Application
    Filed: March 26, 2020
    Publication date: September 17, 2020
    Inventors: Cristina DE MIN, Walter FERLIN, Fabrizio DE BENEDETTI
  • METHODS, COMPOSITIONS AND DOSING REGIMENS FOR TREATING OR PREVENTING INTERFERON-GAMMA RELATED INDICATIONS
    Publication number: 20180142015
    Abstract: The disclosure relates generally to methods compositions and dosing regimens for treating, preventing and/or delaying the onset or progression of, or alleviating a symptom associated with elevated IFN-? levels.
    Type: Application
    Filed: October 24, 2017
    Publication date: May 24, 2018
    Inventors: Cristina de Min, Walter Ferlin, Fabrizio De Benedetti
  • METHODS AND COMPOSITIONS FOR DIAGNOSIS AND TREATMENT OF DISORDERS IN PATIENTS WITH ELEVATED LEVELS OF CXCL9 AND OTHER BIOMARKERS
    Publication number: 20160326244
    Abstract: Methods and compositions for treating hemophagocytic lymphohistiocytosis (HLH) are provided. The disclosure also relates generally to methods and compositions for diagnosing and treating disorders associated with elevated levels of CXCL9, elevated levels of total IFN?, and other biomarkers. The disclosure also relates to methods of treating, delaying the progression of, or otherwise ameliorating a symptom of a disorder in patients with elevated levels of CXCL9 elevated levels of total IFN?, and other biomarkers using agents that interfere with or otherwise antagonize interferon gamma (IFN?) signaling, including neutralizing anti-IFN? antibodies.
    Type: Application
    Filed: May 9, 2016
    Publication date: November 10, 2016
    Inventors: Cristina de Min, Walter Ferlin, Fabrizio De Benedetti